On May 11, 2020, Beroni Group is pleased to announce that its development of a medical solution using nanobody technology for the novel coronavirus (SARS-CoV-2), in collaboration with Tianjin University in China, has made a significant discovery of 24 types of nanobodies for the SARS-CoV-2 virus.
Compared with the traditional antibody, the nanobody has the advantages of high stability, improved screening/isolation techniques, high absorption rate, superior cryptic cleft accessibility, and low immunogenicity. Currently the team is using a wide range of techniques, including structural biology, computational biology and protein engineering, to optimize their properties. By further humanizing the nanobodies, the team has reduced their immunogenicity and enhanced the therapeutic efficacy.
The development of SARS-CoV-2 binding nanobodies will greatly facilitate the treatment of COVID-19. With the discovery of the 24 nanobodies, the research team is now prepared to conduct animal experiments and clinical trials which are expected to yield results within the next 12-18 months.
With the technical capabilities and the team of scientists in the field of biotechnology, Beroni Group efficiently and quickly has been developing medical solutions for COVID-19 since the beginning of the outbreak to fight the virus. News on the progress of the medical solution for COVID-19 being developed by Beroni Group and Tianjin University has been highlighted in several online media sites and have been read many million times.
Links to online media sites:
[YAHOO]
[Biospace]
[Wallstreet]
